» Articles » PMID: 28422282

Analysis of Circulating MiR-1, MiR-23a, and MiR-26a in Atrial Fibrillation Patients Undergoing Coronary Bypass Artery Grafting Surgery

Overview
Journal Ann Hum Genet
Date 2017 Apr 20
PMID 28422282
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Atrial fibrillation (AF) is the most common arrhythmia after cardiac surgery. From a pathophysiological point of view, a myriad of factors such as trauma, atrial dilation, ischemia, mechanical myopericarditis, autonomic imbalance, loss of connexins, AF nest remodeling, inflammation, sutures, and dysfunction caused by postextracorporeal circulation can contribute to postoperative atrial fibrillation (POAF) resulting in a longer hospital stay and consequently higher cost. Recent studies showed that short fragments of RNA, called microRNA (miRNA), can contribute to the development of several cardiovascular diseases, including AF. The aim of this study was to evaluate the levels of circulating miRNAs (miR-1, -23a, and -26a) that can be involved in POAF. Patients submitted to coronary artery bypass graft surgery were grouped in POAF (24 patients) and without POAF (24 patients). Results showed older age, longer clamp-time, and more days in the intensive care unit as well as a longer total hospital stay in the POAF group. Preoperative levels of circulating miRNAs were similar. Analysis of miRNAs revealed significantly lower circulating levels of miRNA-23a (P  =  0.02) and -26a (P  =  0.01) in the POAF group during the postoperative period. Receiver operating characteristic (ROC) analysis showed the area under the ROC curve of miR-23a and miR-26a for predicting FA was 0.63 (95% confidence interval [CI]: 0.51-0.74; P  =  0.02) and 0.66 (95% CI: 0.55-0.77; P  =  0.01), respectively. Our data suggests that circulating miRNA-23a and -26a may be involved in the underlying biology of postoperative AF development.

Citing Articles

Identification of miR-1 and miR-499 in chronic atrial fibrillation by bioinformatics analysis and experimental validation.

Chen X, Zhang Y, Meng H, Chen G, Ma Y, Li J Front Cardiovasc Med. 2024; 11:1400643.

PMID: 39221422 PMC: 11361948. DOI: 10.3389/fcvm.2024.1400643.


The accuracy of the Stroke Risk Analysis (SRA) system for predicting atrial fibrillation in patients in the postoperative period of myocardial revascularization.

Serafim K, Moreira D, da Costa P, Habib R, Reyes C, Fragata C PLoS One. 2023; 18(3):e0282565.

PMID: 36920994 PMC: 10016638. DOI: 10.1371/journal.pone.0282565.


Plasma Extracellular Vesicles as Liquid Biopsy to Unravel the Molecular Mechanisms of Cardiac Reverse Remodeling Following Resynchronization Therapy?.

van Nieuwenhoven F, Schroen B, Barile L, van Middendorp L, Prinzen F, Auricchio A J Clin Med. 2023; 12(2).

PMID: 36675594 PMC: 9862724. DOI: 10.3390/jcm12020665.


Nano drugs delivery system: A novel promise for the treatment of atrial fibrillation.

Wang Z, Tong Q, Li T, Qian Y Front Cardiovasc Med. 2022; 9:906350.

PMID: 36386310 PMC: 9645120. DOI: 10.3389/fcvm.2022.906350.


Leveraging Extracellular Non-coding RNAs to Diagnose and Treat Heart Diseases.

Zhao Z, Guo N, Chen W, Wang Z J Cardiovasc Transl Res. 2022; 15(3):456-468.

PMID: 35419773 DOI: 10.1007/s12265-022-10252-x.